The biotech company reported second-quarter financial results on Friday ahead of market open, a day after announcing plans to ...

The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies find ...

Biotechnology company Moderna (NASDAQ:MRNA) will be reporting results this Friday before the bell. Here’s what to expect.

Analysts have given Moderna a total of 6 ratings, with the consensus rating being Neutral. The average one-year price target ...

US stocks opened under pressure on Friday as investors digested signs of a softening labor market and escalating tariff ...

Biotech firm aims to streamline operations and reinvest in high-growth areas such as oncology and rare diseases as it targets ...

Today, Benzinga 's options scanner spotted 17 uncommon options trades for Moderna. This isn't normal. The overall sentiment of these big-money traders is split between 52% bullish and 35%, bearish.

Meanwhile, if you buy the shares while they're down, you will have gotten in on the stock for a bargain -- and can maximize your potential gains.

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...